Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28438188 | 0.86 | ADORA2A (0.45) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1061386 | 0.86 | ALDH1A1 (0.51) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL1565880 | 0.84 | ALDH1A1 (0.50) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7321782 | 0.84 | ADORA2A (0.46) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL244491 | 0.82 | ALDH1A1 (0.45) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1546702 | 0.78 | CASP6 (0.50) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL5687930 | 0.78 | PDE4A (0.47) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL11604134 | 0.77 | ALDH1A1 (0.38) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL14267075 | 0.76 | ADORA2B (0.45) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL8192033 | 0.76 | ADORA2B (0.50) | ADORA2AADORA2BGLABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8609671-B2 | Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| EP-1789053-B1 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8188099-B2 | Method of decreasing hepatotoxic side effects using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2311462-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7795268-B2 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-5032593-A | Anithistamines | MARION MERRELL DOW INC. (US) | 1991-07-16 | — | — | US | disclosed |
| US-5017577-A | Using Purine Cinnamic Acids | BURROUGHS WELLCOME CO. (US) | 1991-05-21 | — | — | US | disclosed |
| US-5015647-A | Using Purine Cinnamic Acid Compounds | BURROUGHS WELLCOME CO. (US) | 1991-05-14 | — | — | US | disclosed |
| US-4981857-A | ADENOSINE ANTAGONIST | BURROUGHS WELLCOME CO. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0383868-A1 | 1,3-UNSYMMETRICAL STRAIGHT CHAIN ALKYL-SUBSTITUTED 8-PHENYLXANTHINES | MARION LABORATORIES, INC. (US) | 1990-08-29 | — | — | EP | disclosed |
| WO-1990000056-A1 | 1,3-UNSYMMETRICAL STRAIGHT CHAIN ALKYL-SUBSTITUTED 8-PHENYLXANTHINES | MARION LABORATORIES, INC. (US) | 1990-01-11 | — | — | WO | disclosed |
| US-4879296-A | BLOCKING ADERNOSINE CELL SURFACE EFFECTS | BURROUGHS WELLCOME CO. (US) | 1989-11-07 | — | — | US | disclosed |
| US-4783530-A | CARDIOTONIC AND BRONCHODILATOR AGENTS | MARION LABORATORIES, INC. (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0267607-A1 | 8-Arylxanthines | MARION MERRELL DOW INC. (US) | 1988-05-18 | — | — | EP | disclosed |
| EP-0203721-A2 | 8-Phenyl xanthines | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PDE4A 259/4885ADORA2A 2/4885PDE4B 176/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PDE4A 259/4885ADORA2A 2/4885PDE4B 176/4885 |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PDE4A 71/4885ADORA2A 2/4885PDE4B 50/4885 |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PDE4A 295/4885ADORA2A 2/4885PDE4B 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.